Fresenius Medical Care has reported a net income of €213m, or €0.73 per share, for the third quarter ended 30 September 2024, a 153% increase compared to €84m, or €0.29 per share, for the respective period in 2023.
The dialysis services provider’s net income for the third quarter (Q3) of 2024 increased by 14% compared to €187m for the second quarter of 2024 (Q2) 2024.
Fresenius reported total revenue of €4.76bn for Q3 2024, a 4% decline compared to €4.93bn for the same quarter in 2023, and unchanged compared to Q2 2024.
The company reported an income before tax of €381m for Q3 2024, a 62% increase compared to €235m for the respective quarter in the previous year.
Fresenius reported an operating income of €463m for Q3 2024, a 43% rise compared to €324m for the same period in 2023.
The company attributed the decrease in revenues to divestments realised as part of the portfolio optimisation plan, which was partially offset by organic growth.
Fresenius Medical Care CEO Helen Giza said: “In the third quarter, we continued the improvement of our financial performance, recording a meaningful progress in the operating income margin towards our 2025 margin targets.
“The Care Delivery margin extended well into the 2025 margin target band while Care Enablement maintained the significant margin progress realized in the first half year.
“Our clear focus on improving operational performance and continued momentum of FME25 savings realisation supported our progress in the third quarter.”
Fresenius reported a net income of €471m, or €1.61 per share, for the first nine months (9M) of 2024, a 51% increase compared to €311m, or €1.06 per share, for the same period in 2023.
The company reported total revenue of €14.25bn for 9M 2024, a 1.5% decline compared to €14.46bn for the respective period in the previous year.
The dialysis services provider reported an income before tax of €877m for 9M 2024, a 27% increase compared to €690m for the same period in 2023.
Fresenius reported an operating income of €1.13bn for 9M 2024, a 20% increase compared to €942m for the corresponding nine months in 2023.
Giza added: “In Care Delivery, a very important and reassuring milestone was underlying U.S. same market treatment growth turning positive. Care Enablement recorded solid volume growth and continued positive pricing momentum outside China.”
“In light of the developments in the first nine months, we confirm our revenue growth outlook and tighten our operating income growth outlook with 16-18% toward the upper end of the previous range for the full year 2024.”
